A short clip from a longer interview about where oral GLP-1 receptor agonists are headed. The full conversation is on video and Spotify.
Recap by typeshit. Post by @medicalupdateonline on Instagram.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
The interim access policy, requested by the American Academy of Peptide Medicine, now awaits OMB review. The group's chair says it would help squeeze out gray-market sellers.
Lilly is going after sellers of its experimental obesity drug, which has not been approved for human use but is already being sold online.
Loading…